Take­da-backed Mer­sana joins the biotech IPO queue with a $75M of­fer­ing and am­bi­tious plans for ADC tech

A lit­tle more than a year af­ter an am­bi­tious Take­da came in with a $1 bil­lion-plus pack­age to col­lab­o­rate with Mer­sana on its an­ti­body/drug con­structs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.